Round Details
Longevium, a UAE-based healthtech company, has raised $7 million in its first funding round. The capital is earmarked for construction and operation of an AI-powered longevity research laboratory in Dubai, focused on predictive health analytics and biological aging measurement.
The lab is scheduled to open in Q4 2026.
What Longevium Is Building
The company is developing an integrated platform that combines:
- Multi-omic biological age measurement — genomic, proteomic, metabolomic, and epigenetic data to generate a composite biological age score
- AI-driven predictive models — machine learning algorithms that identify early markers of age-related decline before clinical symptoms appear
- Personalized intervention protocols — data-driven recommendations for lifestyle, supplementation, and medical interventions calibrated to individual biological trajectories
Why Dubai
The UAE has emerged as a global hub for longevity research and investment in 2026:
- National strategy alignment: The UAE's Quality of Life Strategy explicitly targets life extension and healthy aging as national priorities
- Regulatory speed: Dubai's healthcare free zones offer faster regulatory pathways for novel diagnostics and health technologies
- Capital concentration: Gulf sovereign wealth funds (M42, Mubadala, PIF) have collectively deployed over $500M into longevity startups in the past year
- Medical tourism: Dubai already attracts significant medical tourism traffic, providing a built-in patient base for precision health services
Funding Snapshot
| Detail | Value |
|---|---|
| Company | Longevium |
| Round | First funding round |
| Amount | $7 million |
| HQ | UAE (Dubai) |
| Focus | AI-powered longevity research lab |
| Lab opening | Q4 2026 |
